GlobeNewswire: Dimension Therapeutics Contains the last 10 of 46 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:48:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/10/02/1138698/0/en/Dimension-Board-Determines-that-Ultragenyx-s-Unsolicited-Proposal-to-Acquire-Dimension-for-6-00-Per-Share-Constitutes-a-Superior-Proposal.html?f=22&fvtc=4&fvtv=27475Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”2017-10-02T12:00:00Z<![CDATA[REGENXBIO Waives Matching Rights]]>https://www.globenewswire.com/news-release/2017/09/19/1124603/0/en/Dimension-Board-of-Directors-Determines-Proposal-from-Ultragenyx-Pharmaceutical-Inc-Could-Reasonably-Be-Expected-to-Lead-to-a-Superior-Proposal.html?f=22&fvtc=4&fvtv=27475Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”2017-09-19T12:00:00Z<![CDATA[Dimension to Begin Discussions with Ultragenyx Dimension to Begin Discussions with Ultragenyx]]>https://www.globenewswire.com/news-release/2017/09/18/1124299/0/en/Dimension-Confirms-Receipt-of-Unsolicited-Proposal-from-Ultragenyx.html?f=22&fvtc=4&fvtv=27475Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx2017-09-18T19:10:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) (“Ultragenyx”) to acquire Dimension for $5.50 per share in cash to be effectuated via a tender offer. Ultragenyx publicly announced this proposal today and the proposal is subject to, among other things, diligence to be conducted, various closing conditions, Dimension stockholder approval and regulatory approvals.]]>https://www.globenewswire.com/news-release/2017/08/31/1106094/0/en/Dimension-Therapeutics-Commences-Patient-Dosing-in-Global-Multi-Center-Phase-1-2-Clinical-Trial-of-DTX301-in-Ornithine-Transcarbamylase-OTC-Deficiency.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency2017-08-31T12:00:00Z<![CDATA[Twelve trial sites recruiting patients with OTC deficiency in the United States, United Kingdom, Spain, and Canada]]>https://www.globenewswire.com/news-release/2017/08/08/1081542/0/en/Dimension-Therapeutics-Reports-Second-Quarter-2017-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update2017-08-08T12:00:00Z<![CDATA[Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017]]>https://www.globenewswire.com/news-release/2017/07/24/1056089/0/en/Dimension-Therapeutics-Announces-Management-Change.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Announces Management Change2017-07-24T12:00:00Z<![CDATA[CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Jean Franchi, Chief Financial Officer, has resigned in order to pursue other opportunities, effective July 28, 2017.]]>https://www.globenewswire.com/news-release/2017/06/27/1029481/0/en/Dimension-Therapeutics-Completes-Strategic-Review-and-Updates-Corporate-Priorities.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities2017-06-27T12:00:00Z<![CDATA[Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017]]>https://www.globenewswire.com/news-release/2017/05/10/981771/0/en/Dimension-Therapeutics-Reports-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update2017-05-10T12:00:00Z<![CDATA[Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B]]>https://www.globenewswire.com/news-release/2017/04/24/970418/0/en/Dimension-Therapeutics-Announces-Presentations-at-the-Upcoming-American-Society-for-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting2017-04-24T16:05:00Z<![CDATA[CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced poster presentations that highlight technology underpinning select product candidate programs. The presentations will occur during the 20th ASGCT Annual Meeting, which is taking place in Washington, DC, May 10-13, 2017.]]>https://www.globenewswire.com/news-release/2017/03/09/933847/0/en/Dimension-Therapeutics-Announces-Full-Year-2016-Financial-Results-and-Recent-Updates-Across-Rare-and-Metabolic-Disease-Portfolio-and-in-HeLa-Manufacturing.html?f=22&fvtc=4&fvtv=27475Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing2017-03-09T12:30:00Z<![CDATA[In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017]]>